Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Oct 10;7(19):5733-5742.
doi: 10.1182/bloodadvances.2022008524.

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Raphaelle Aubrais  1 , Krimo Bouabdallah  1 , Loic Chartier  2 , Charles Herbaux  3 , Anne Banos  4 , Pauline Brice  5 , David Sibon  6 , Jean Marc Schiano  7 , Thomas Cluzeau  8 , Kamel Laribi  9 , Ronan Le Calloch  10 , Mathieu Bellal  11 , Baptiste Delapierre  11 , Nicolas Daguindau  12 , Sandy Amorim  13 , Kossi Agbetiafa  14 , Adrien Chauchet  15 , Caroline Besson  16 , Eric Durot  17 , Christophe Bonnet  18 , Ludovic Fouillet  19 , Fontanet Bijou  20 , Olivier Tournilhac  21 , Philippe Gaulard  22 , Marie-Cécile Parrens  23 , Gandhi Damaj  11
Affiliations
Multicenter Study

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Raphaelle Aubrais et al. Blood Adv. .

Abstract

Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: G.D., K.B., O.T., D.S., and P.B. received travel grant from Takeda. G.D. received travel grant from AbbVie, Pfizer, and is a member on the scientific board for blueprint of Takeda, AbbVie, and Roche. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Survival for the whole cohort. (A) PFS and (B) OS.
Figure 2.
Figure 2.
PFS and OS according to response. (A) PFS according to response (PR/CR vs SD/PD). (B) OS according to response (PR/CR vs SD/PD).
Figure 3.
Figure 3.
PFS and OS according to allotransplantation for patients in CR or PR (Landmark approach). (A) PFS according to allotransplantation status for patients in CR or PR. (B) OS according to transplantation status for patients in CR or PR only.
Figure 4.
Figure 4.
PFS and OS according to transplantation status for patients in CR (Landmark approach). (A) PFS according to transplantation status for patients in CR only. (B) OS according to transplantation status for patients in CR only.
See this image and copyright information in PMC

References

    1. Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol. 2017;35(18):2008–2017. - PubMed
    1. De Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361–e364. - PMC - PubMed
    1. Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191–1197. - PMC - PubMed
    1. Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750–758. - PMC - PubMed
    1. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–1976. - PubMed

Publication types

MeSH terms

Substances